Norma C. Gutiérrez - Concepedia

Author

Norma C. Gutiérrez

Centro de Investigación del Cáncer ORCID

Also Known As

Enrique Bengoechea, Gutierrez, N.C., GutiÉrrez, Gutiérrez, Norma C., Juan L. García, M-B Vidriales, M. Belén González, Michael Grossbard, N C Gutierrez, N C Gutiérrez

502

Publications

15.6K

Citations

H-Index

109

Concepts

All Affiliations

Centro de Investigación del Cáncer Universidad de Salamanca Instituto de Investigación Biomédica de Salamanca Complejo Hospitalario de Salamanca Centro de Investigación Biomédica en Red de Cáncer

About

Norma C. Gutiérrez is an author at Centro de Investigación del Cáncer specializing in medicine, hematology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	40	65	5.7K
2	Health Sciences	15	16	1.7K
3	Engineering	4	4	259
4	Natural Sciences	3	3	266
5	Biomedical Engineering	1	1	13

Norma C. Gutiérrez

175

Publications

13.5K

Citations

H-Index

Page 1

	Year	Citations
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study Laura Rosiñol, Albert Oriol, Ana Isabel Teruel, Blood	2012	485
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation Bruno Paiva, María‐Belén Vídriales, Jorge Cerveró, Blood	2008	463
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López, The Lancet Oncology Hematological MalignancyElderly PatientsMedicineRandomised TrialHematology	2010	459
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study María‐Victoria Mateos, JoséM. Hernández, M.B. Gómez Hernández, Blood	2006	388
Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification Jesús F. San Miguel, María‐Belén Vídriales, C López-Berges, Blood	2001	331
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders F. M. Ross, Hervé Avet‐Loiseau, Geneviève Ameye, Haematologica Mixed-phenotype Acute LeukemiaImmunologyPathologyHematological MalignancyLaboratory Hematology	2012	317
Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers Carlos A. Morillo, Hetty Waskin, Sergio Sosa‐Estáni, Journal of the American College of Cardiology Eliminating ParasitesParasitic DiseaseAntiparasitic AgentMedicineParasitic Protozoa	2017	309
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials Juan José Lahuerta, Bruno Paiva, María‐Belén Vídriales, Journal of Clinical Oncology Hematological MalignancyPrognostic EvaluationMrd NegativityOncologyTransplantation	2017	305
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma Bruno Paiva, Norma C. Gutiérrez, Laura Rosiñol, Blood	2011	303
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms Brian A. Walker, Christopher P. Wardell, Lorenzo Melchor, Leukemia Hematological MalignancyClinical SymptomsMixed-phenotype Acute LeukemiaMalignant Blood DisorderHematology	2013	281

Page 1